Analysts at HC Wainwright assumed coverage on shares of MiNK Therapeutics (NASDAQ:INKT - Get Free Report) in a report released on Wednesday. The firm set a "buy" rating and a $38.00 price target on the stock. HC Wainwright's price objective points to a potential upside of 252.18% from the company's current price.
Several other analysts have also recently commented on the stock. Zacks Research cut shares of MiNK Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Finally, B. Riley Financial reiterated a "buy" rating and set a $50.00 target price (up from $43.00) on shares of MiNK Therapeutics in a research report on Wednesday, October 21st. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, MiNK Therapeutics has a consensus rating of "Hold" and an average target price of $44.00.
Check Out Our Latest Analysis on INKT
MiNK Therapeutics Price Performance
MiNK Therapeutics stock opened at $10.79 on Wednesday. MiNK Therapeutics has a 12 month low of $8.48 and a 12 month high of $16.93. The business has a 50 day simple moving average of $11.31 and a 200-day simple moving average of $11.29. The stock has a market capitalization of $55.03 million, a PE ratio of -4.50 and a beta of 0.49.
MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.02). As a group, equities research analysts anticipate that MiNK Therapeutics will post -2.20 EPS for the current year.
Insider Activity at MiNK Therapeutics
In related news, CEO Jennifer Buell sold 6,938 shares of the firm's stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the sale, the chief executive officer owned 74,195 shares in the company, valued at $783,499.20. This trade represents a 8.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 20.40% of the stock is owned by company insiders.
MiNK Therapeutics Company Profile
(
Get Free Report)
MiNK Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company's platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses.
MiNK's lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MiNK Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiNK Therapeutics wasn't on the list.
While MiNK Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.